NCT00476099View on ClinicalTrials.gov

Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD

PHASE3CompletedINTERVENTIONAL
Enrollment

828

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

November 30, 2008

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI

Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.

DRUG

Budesonide 200 µg plus formoterol 6 µg DPI

two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.

DRUG

Formoterol 12 µg DPI

one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.

Trial Locations (1)

75000

Thomas Similowski, Paris

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT00476099 - Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD | Biotech Hunter | Biotech Hunter